UA83510C2 - N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b - Google Patents
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b Download PDFInfo
- Publication number
- UA83510C2 UA83510C2 UAA200605783A UAA200605783A UA83510C2 UA 83510 C2 UA83510 C2 UA 83510C2 UA A200605783 A UAA200605783 A UA A200605783A UA A200605783 A UAA200605783 A UA A200605783A UA 83510 C2 UA83510 C2 UA 83510C2
- Authority
- UA
- Ukraine
- Prior art keywords
- aai
- dar
- bibiove
- yair
- spol
- Prior art date
Links
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 2
- 101710095342 Apolipoprotein B Proteins 0.000 title 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 241001142392 Bibio Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 5
- 229950001870 spizofurone Drugs 0.000 description 5
- 244000236580 Psidium pyriferum Species 0.000 description 4
- 235000013929 Psidium pyriferum Nutrition 0.000 description 4
- 101100484538 Caenorhabditis elegans vav-1 gene Proteins 0.000 description 2
- 240000000018 Gnetum gnemon Species 0.000 description 2
- 101100056293 Rattus norvegicus Akr7a2 gene Proteins 0.000 description 2
- 101150042678 VAV1 gene Proteins 0.000 description 2
- 229940106943 azor Drugs 0.000 description 2
- MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
- 241000258740 Abia Species 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000566146 Asio Species 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 241000994536 Biza Species 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 241000435574 Popa Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000256834 Vespula vulgaris Species 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- YLBMNMLHAAOXAL-UHFFFAOYSA-N aziv Chemical compound O1C(C)=C(O)C(=O)CC1OC1C2(C)CCC3(C)C4(C)CCC5C(C)(CO)C(OC6C(C(O)C(O)C(O6)C(O)=O)OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC=C3C2CC(C)(C)C1 YLBMNMLHAAOXAL-UHFFFAOYSA-N 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104601 | 2003-12-09 | ||
| PCT/EP2004/053280 WO2005058824A2 (en) | 2003-12-09 | 2004-12-06 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83510C2 true UA83510C2 (en) | 2008-07-25 |
Family
ID=34684566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200605783A UA83510C2 (en) | 2003-12-09 | 2004-06-12 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8772494B2 (ru) |
| EP (1) | EP1694644B1 (ru) |
| JP (1) | JP4790626B2 (ru) |
| KR (1) | KR101125120B1 (ru) |
| CN (1) | CN100548985C (ru) |
| AT (1) | ATE548350T1 (ru) |
| AU (1) | AU2004299295B2 (ru) |
| BR (1) | BRPI0417469B8 (ru) |
| CA (1) | CA2547243C (ru) |
| EA (1) | EA009081B1 (ru) |
| ES (1) | ES2383179T3 (ru) |
| HK (1) | HK1100559A1 (ru) |
| IL (1) | IL176171A (ru) |
| NO (1) | NO337251B1 (ru) |
| NZ (1) | NZ546964A (ru) |
| SG (1) | SG149001A1 (ru) |
| UA (1) | UA83510C2 (ru) |
| WO (1) | WO2005058824A2 (ru) |
| ZA (1) | ZA200604718B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1948629A1 (en) * | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| JP5198430B2 (ja) | 2006-04-03 | 2013-05-15 | サンタリス ファーマ アー／エス | ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物 |
| MY162210A (en) | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
| US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| JP2010521193A (ja) | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー／エス | Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物 |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| ES2463665T3 (es) | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| AU2009221064B2 (en) | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
| ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| RS59986B1 (sr) | 2013-06-27 | 2020-03-31 | Roche Innovation Ct Copenhagen As | Antisens oligomeri i konjugati koji ciljno deluju na pcsk9 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| GB0109287D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
-
2004
- 2004-06-12 UA UAA200605783A patent/UA83510C2/uk unknown
- 2004-12-06 WO PCT/EP2004/053280 patent/WO2005058824A2/en active Application Filing
- 2004-12-06 NZ NZ546964A patent/NZ546964A/en not_active IP Right Cessation
- 2004-12-06 ES ES04804685T patent/ES2383179T3/es active Active
- 2004-12-06 BR BRPI0417469A patent/BRPI0417469B8/pt not_active IP Right Cessation
- 2004-12-06 CA CA2547243A patent/CA2547243C/en not_active Expired - Fee Related
- 2004-12-06 AT AT04804685T patent/ATE548350T1/de active
- 2004-12-06 EP EP04804685A patent/EP1694644B1/en active Active
- 2004-12-06 JP JP2006543538A patent/JP4790626B2/ja not_active Expired - Fee Related
- 2004-12-06 SG SG200809026-8A patent/SG149001A1/en unknown
- 2004-12-06 CN CNB2004800362613A patent/CN100548985C/zh not_active Expired - Fee Related
- 2004-12-06 AU AU2004299295A patent/AU2004299295B2/en not_active Ceased
- 2004-12-06 KR KR1020067013049A patent/KR101125120B1/ko active IP Right Grant
- 2004-12-06 US US10/580,530 patent/US8772494B2/en not_active Expired - Fee Related
- 2004-12-06 EA EA200601120A patent/EA009081B1/ru not_active IP Right Cessation
-
2006
- 2006-06-07 IL IL176171A patent/IL176171A/en active IP Right Grant
- 2006-06-08 ZA ZA200604718A patent/ZA200604718B/en unknown
- 2006-07-04 NO NO20063103A patent/NO337251B1/no not_active IP Right Cessation
-
2007
- 2007-05-30 HK HK07105744.1A patent/HK1100559A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005058824A2 (en) | 2005-06-30 |
| JP2007513921A (ja) | 2007-05-31 |
| AU2004299295B2 (en) | 2010-07-15 |
| ZA200604718B (en) | 2007-10-31 |
| JP4790626B2 (ja) | 2011-10-12 |
| EP1694644B1 (en) | 2012-03-07 |
| ATE548350T1 (de) | 2012-03-15 |
| IL176171A (en) | 2013-08-29 |
| CN100548985C (zh) | 2009-10-14 |
| BRPI0417469B8 (pt) | 2021-05-25 |
| NO337251B1 (no) | 2016-02-22 |
| NO20063103L (no) | 2006-09-05 |
| KR20060111628A (ko) | 2006-10-27 |
| WO2005058824A3 (en) | 2005-10-27 |
| US20070099934A1 (en) | 2007-05-03 |
| CN1890217A (zh) | 2007-01-03 |
| US8772494B2 (en) | 2014-07-08 |
| CA2547243A1 (en) | 2005-06-30 |
| EP1694644A2 (en) | 2006-08-30 |
| AU2004299295A1 (en) | 2005-06-30 |
| KR101125120B1 (ko) | 2012-03-21 |
| BRPI0417469A (pt) | 2007-04-10 |
| SG149001A1 (en) | 2009-01-29 |
| HK1100559A1 (en) | 2007-09-21 |
| CA2547243C (en) | 2012-10-23 |
| EA009081B1 (ru) | 2007-10-26 |
| ES2383179T3 (es) | 2012-06-18 |
| EA200601120A1 (ru) | 2006-10-27 |
| NZ546964A (en) | 2009-03-31 |
| IL176171A0 (en) | 2006-10-05 |
| BRPI0417469B1 (pt) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83510C2 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
| ES2431353T3 (es) | Monómero de polisiloxano hidrofílico, y método de producción y aplicación del mismo | |
| ES2371754T3 (es) | BANDA DE ALEACIÓN AMORFA A BASE DE Fe. | |
| ES2329272T3 (es) | Prepolimeros de polisiloxano para dispositivos biomedicos. | |
| ES2387351T3 (es) | Lentes oftálmicos para uso extendido | |
| ES2808605T3 (es) | Vidrio exento de litio con módulo mejorado | |
| ES2335892T3 (es) | Dispersion de poliuretano (pud) con resistencia al isopropanol, flexibilidad y suavidad mejoradas. | |
| US7418231B2 (en) | Cleaning blade member | |
| US9045396B2 (en) | Hydrolysable linkers and cross-linkers for absorbable polymers | |
| DE602008003124D1 (en) | 1-butenethylencopolymere | |
| DE50214303D1 (de) | Reaktive polyurethan-zusammensetzungen mit niedrigem restmonomergehalt | |
| JP2009520058A (ja) | 硫黄含有オリゴマーおよびそれから調製された高指数ポリウレタン | |
| JP2004505137A5 (ru) | ||
| CN102448449A (zh) | 粘贴材料 | |
| BR0111948A (pt) | Composição para entrega de fator de crescimento hematopoiético | |
| CA2449369A1 (en) | Synergistic amine chain-extenders in polyurea spray elastomers | |
| RU2012149352A (ru) | Полиуретановый балластный слой, способ получения такого слоя и его применение | |
| EP2308914A1 (en) | Polycarbonate diol and polycarbonate diol copolymer | |
| ES2672353T3 (es) | Composición para la preparación de fibras cerámicas y fibras cerámicas biosolubles preparadas a partir de la misma para un material aislante del calor a alta temperatura | |
| ES2897458T3 (es) | Elastómeros termoplásticos de poliuretano-urea procesables por fusión | |
| US20050228160A1 (en) | Golf ball compositions with improved temperature performance, heat resistance, and resiliency | |
| Bouraoui et al. | Substitution of unsaturated lipid chains by thioether-containing lipid chains in cationic amphiphiles: physicochemical consequences and application for gene delivery | |
| US8501878B2 (en) | Method for producing polycarbonate material having excellent solubility and affinity, and contact lens material comprising the same | |
| KR20150095771A (ko) | 플루오렌계 중합체, 플루오렌계 디올 화합물 및 그 제조 방법 | |
| US20050228146A1 (en) | Golf ball compositions with improved temperature performance, heat resistance, and resiliency |